MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) is a publicly traded Healthcare sector company. As of July 14, 2026, MLTX trades at $20.47 with a market cap of $1.70B and a P/E ratio of -5.72. MLTX moved +0.25% today. Year to date, MLTX is +54.50%; over the trailing twelve months it is -58.35%. Its 52-week range spans $5.95 to $62.75. Analyst consensus is buy with an average price target of $34.44. Rallies surfaces MLTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for MLTX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $20.47 |
| Market Cap | $1.70B |
| P/E Ratio | -5.72 |
| EPS | $-3.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.75 |
| 52-Week Low | $5.95 |
| Volume | 1.20M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-230.32M |
| Gross Margin | 0.00% |
10 analysts cover MLTX: 0 strong buy, 8 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $34.44.